Mallinckrodt PLC (MNKKQ)
| Market Cap | 22.33M |
| Revenue (ttm) | 2.11B |
| Net Income (ttm) | -1.04B |
| Shares Out | 84.71M |
| EPS (ttm) | -12.28 |
| PE Ratio | n/a |
| Forward PE | 0.45 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $0.2500 |
| Previous Close | $0.2500 |
| Change ($) | 0.0000 |
| Change (%) | 0.00% |
| Day's Open | 0.2640 |
| Day's Range | 0.2450 - 0.2640 |
| Day's Volume | 221,391 |
| 52-Week Range | 0.0652 - 3.6600 |
DUBLIN, May 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy a...
DUBLIN, April 30, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing the safety and e...
Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said had received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties. In 2019, ...
ST. LOUIS, March 29, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that its Specialty Generics division has been recognized as Manufacturin...
DUBLIN, March 10, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien term lenders h...
DUBLIN, March 4, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safet...
Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it will receive US$2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focuse...
Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices ...
Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.
DUBLIN, Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring...
Mallinckrodt (MNKKQ) closed the most recent trading day at $0.50, moving -1.76% from the previous trading session.
DUBLIN, Jan. 29, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equal...
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending...
Mallinckrodt (MNKKQ) closed the most recent trading day at $0.23, moving +1.7% from the previous trading session.
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending...
Top Ranked Value Stocks to Buy for December 21st
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 17th
DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patients hospit...
DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipressin in pati...
DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 E...
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in adults with hep...
ROCKFORD, Ill.--(BUSINESS WIRE)--In April 2017, Rockford sued Mallinckrodt and Express Scripts for antitrust violations. Rockford's lawsuit seeks to return more than $10 billion...
DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for it...
Here's what you should know
Shares of Mallinckrodt Plc tumbled 31.2% in trading on Monday after the company said it had filed for Chapter 11 bankruptcy, in part due to a proposed billion-dollar settlement for its alleged role in t...
Mallinckrodt Pharmaceuticals, facing billions of dollars in legal costs over its role in the nation's opiod crisis, filed for bankruptcy early Monday.
Drug manufacturer Mallinckrodt PLC (NYSE: MNK) disclosed Monday that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court to restructure its operations and pare do...
Mallinckrodt Plc filed for bankruptcy protection on Monday in the face of lawsuits alleging it fueled the U.S. opioid epidemic and after the drugmaker lost a court battle to avoid paying higher rebates ...
Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring
DUBLIN, Oct. 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court...
A House committee has issued detailed reports about some of their drug price increases.
Terlipressin's rejection is a huge blow to the diversification effort, but likely a delay rather than a scrapping of the entire program.
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
The proposed law now goes to Gov. Gavin Newsom for his signature.
ST. LOUIS, Aug. 24, 2020 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been recognized as a Manuf...
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
STAINES-UPON-THAMES, United Kingdom, Aug. 10, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Mallinckrodt plc (MNK) CEO Mark Trudeau on Q2 2020 Results - Earnings Call Transcript
Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Mallinckrodt PLC MNK, -23.00% plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted...
Shares of Mallinckrodt (NYSE:MNK) decreased 24% in pre-market trading after the company reported Q2 results.
Shares of Mallinckrodt PLC MNK, +1.34% rose 0.9% in premrket trading Tuesday, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat expectations...
DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a decline of 14.9%...
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
About MNKKQ
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1867 |
| CEO Mark Trudeau | Employees 3,072 |
| Stock Exchange OTCMKTS | Ticker Symbol MNKKQ |
Financial Performance
In 2020, Mallinckrodt's revenue was $2.21 billion, a decrease of -30.01% compared to the previous year's $3.16 billion. Losses were -$944.60 million, -5.21% less than in 2019.